BioMarin Pharmaceutical Set to Report Q4 Earnings on February 23

BioMarin Pharmaceutical (NASDAQ: BMRN) is scheduled to release its fourth-quarter earnings results after the market closes on February 23, 2026. Investors will focus on whether the biotech firm can reverse a trend of missed revenue estimates recorded over the past two years. Analysts anticipate an 11.6% year-over-year revenue increase, a deceleration from the 15.6% growth posted in the same quarter last year. In the previous quarter, the company reported revenues of $776.1 million, meeting expectations but missing EPS projections. Despite sector-wide underperformance, BioMarin shares gained 13.9% over the last month. The average analyst price target stands at $88.87, compared to the current share price of $64.08.